OTCMKTS:OPHLY Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free OPHLY Stock Alerts $4.75 -0.02 (-0.42%) (As of 06/3/2024 ET) Add Compare Share Share Today's Range$4.58▼$4.7650-Day Range$4.57▼$5.5452-Week Range$4.57▼$6.74Volume94,618 shsAverage Volume109,788 shsMarket CapitalizationN/AP/E Ratio1.04Dividend Yield348.56%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Ono Pharmaceutical alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Ono Pharmaceutical Stock (OTCMKTS:OPHLY)Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.Read More OPHLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPHLY Stock News HeadlinesMay 8, 2024 | markets.businessinsider.comOno Pharmaceutical is about to announce its earnings — here's what to expectApril 30, 2024 | reuters.comJapan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansionApril 29, 2024 | msn.comDeciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 BillionApril 29, 2024 | marketwatch.comDeciphera Pharmaceuticals Gets $2.4B Buyout Offer From ONO PharmaceuticalApril 29, 2024 | markets.businessinsider.comONO To Acquire Deciphera; Total Equity Value Of Deal At Approx. $2.4 BlnApril 29, 2024 | reuters.comJapan's ONO Pharmaceutical to buy Deciphera for $2.4 billionMarch 6, 2024 | msn.comOno signs licence deal with NEX-I for cancer therapyFebruary 26, 2024 | finance.yahoo.comFate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 19, 2024 | markets.businessinsider.comInveniAI Announces Collaboration with Ono Pharmaceutical for Target DiscoveryFebruary 15, 2024 | finance.yahoo.comOno Pharmaceutical Co., Ltd. (OPHLY)February 14, 2024 | globenewswire.comNumab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of CancerFebruary 10, 2024 | barrons.comOno Pharmaceutical Co. Ltd.January 30, 2024 | markets.businessinsider.comOno Pharmaceutical earnings preview: what Wall Street is expectingJanuary 9, 2024 | finance.yahoo.comCall for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed XDecember 19, 2023 | finanznachrichten.deThe BioMed X Institute: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer ResearchNovember 28, 2023 | finance.yahoo.comNikkei Edges 0.2% Lower Amid JPY StrengthNovember 27, 2023 | finance.yahoo.comChina Shares Open Lower; Infrastructure Stocks WeighOctober 5, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 10.78% to 7.59August 31, 2023 | finance.yahoo.comTwist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune DiseasesAugust 31, 2023 | markets.businessinsider.comTwist Bioscience To Develop Novel Antibodies With Ono PharmaAugust 9, 2023 | finance.yahoo.comQ2 2023 Fate Therapeutics Inc Earnings CallAugust 3, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Decreased by 29.33% to 6.89March 23, 2023 | technews.tmcnet.comMacomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of CancerNovember 1, 2022 | benzinga.comMemo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology TargetsSeptember 19, 2022 | finance.yahoo.com3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth StockSee More Headlines Receive OPHLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:OPHLY CUSIPN/A CIK940821 Webwww.ono.co.jp Phone(166) 263-5670FaxN/AEmployees3,761Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio1.04 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Gyo Sagara (Age 66)CEO, President & Representative Director Comp: $894.2kMr. Masaki ItoCorp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. TaxTakehiro YamadaCorporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion OfficeMasayuki TanigawaCorporate Officer & Executive Director of Corporate Development & StrategyMr. Toichi Takino Ph.D. (Age 56)Senior Managing Executive Officer, Head of Research Division & Director Mr. Toshihiro Tsujinaka (Age 60)Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director Hiromu Habashita Ph.D.Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of ImmunologyKiyoaki Idemitsu (Age 60)Managing Executive Officer, GM of Development Division & Director Shinji Takai M.D.Ph.D., Corporate Officer & Head of Medical AffairsSatoshi TakahagiCorporate Officer and Executive Director of Sales, Marketing & Primary Care Business DivisionMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFKyowa KirinOTCMKTS:KYKOFView All Competitors OPHLY Stock Analysis - Frequently Asked Questions How have OPHLY shares performed in 2024? Ono Pharmaceutical's stock was trading at $5.86 on January 1st, 2024. Since then, OPHLY stock has decreased by 18.6% and is now trading at $4.77. View the best growth stocks for 2024 here. Are investors shorting Ono Pharmaceutical? Ono Pharmaceutical saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 37,200 shares, an increase of 126.8% from the April 30th total of 16,400 shares. Based on an average daily trading volume, of 216,300 shares, the days-to-cover ratio is presently 0.2 days. View Ono Pharmaceutical's Short Interest. Is Ono Pharmaceutical a good dividend stock? Ono Pharmaceutical (OTCMKTS:OPHLY) pays an annual dividend of $16.56 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 362.62%. Payout ratios above 75% are not desirable because they may not be sustainable. How do I buy shares of Ono Pharmaceutical? Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OPHLY) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s Silent Partners?Weiss RatingsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceThe Only Energy Play You Should Be Looking AtWealthpin Pro[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyCollapse of the Petrodollar Colonial Metals[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.